| Literature DB >> 30261360 |
Daouia I Larabi1, Lisette van der Meer2, Gerdina H M Pijnenborg3, Branislava Ćurčić-Blake4, André Aleman5.
Abstract
BACKGROUND: Insight is impaired in the majority of schizophrenia patients. The exact neural correlates of impaired insight remain unclear. We assume that the ability to regulate emotions contributes to having good clinical insight, as patients should be able to regulate their emotional state in such a way that they can adapt adequately in order to cope with impaired functioning and negative stigma associated with a diagnosis of schizophrenia. Numerous studies have shown emotional dysregulation in schizophrenia. We investigated the association between insight and brain activation and connectivity during emotion regulation.Entities:
Keywords: Cognitive reappraisal; Emotion regulation; Expressive suppression; Insight; fMRI; gPPI
Mesh:
Year: 2018 PMID: 30261360 PMCID: PMC6154769 DOI: 10.1016/j.nicl.2018.09.009
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Fig. 1Model of impaired insight in schizophrenia. Adapted from Pijnenborg et al. (2011).
Fig. 2Visualization of hypotheses.
Clinical and demographic characteristics of all participants.
| Variable | Schizophrenia patients (mean (SD)) | Healthy controls (mean (SD)) | Significance |
|---|---|---|---|
| Age (years) | 35.00 (10.16) (range: 20–57) | 33.60 (11.11) (range: 21–53) | F(1,43) = 0.178, p = 0.675 |
| Sex (percentage male) | 73% | 67% | χ(1) = 0.216, p = 0.642 |
| Level of education | 5.37 (1.16) | 5.60 (0.91) | U = 202.5, p = 0.571 |
| Self-reported handedness (percentage right-handed) | 87% | 87% | χ(1) = 0, p = 1 |
| Estimate of premorbid intelligence | 98.00 (16.30) | 93.1 (10.05) | F(1,42) = 1.508, p = 0.226 |
| Age of illness onset (years) | 23.83 (7.73) | ||
| Illness duration (years) | 11.10 (8.60) | ||
| Use of antipsychotic medication | |||
| None | 2 | ||
| Olanzapine | 14 | ||
| Aripiprazole | 12 | ||
| Quetiapine | 5 | ||
| Clozapine | 3 | ||
| Haloperidol | 1 | ||
| Perphenazine | 1 | ||
| Pimozide | 1 | ||
| Risperidone | 1 | ||
| PANSS | |||
| Negative symptoms | 14.27 (4.61) | ||
| Positive symptoms | 14.47 (5.47) | ||
| General psychopathology | 29.17 (7.73) | ||
| Total | 57.90 (14.71) | ||
| SAI-E | |||
| Awareness of illness | 8.84 (3.49) | ||
| Relabeling of symptoms | 3.57 (2.14) | ||
| Need for treatment | 1.70 (0.70) | ||
| Subtotal | 15.93 (7.21) | ||
| BCIS | |||
| Self-reflection | 9.83 (4.20) | ||
| Self-certainty | 15.87 (5.16) | ||
| Composite score | 6.03 (5.01) |
Abbreviations: PANSS = Positive and Negative Syndrome Scale; SAI-E = Schedule for the Assessment of Insight – Expanded; BCIS = Beck Cognitive Insight Scale.
No significant differences were found between groups in age (tested with ANOVA), sex (tested with Chi-Square test), level of education (tested with Mann-Whitney U Test), handedness (tested with Chi-Square test) and estimate of premorbid intelligence (tested with ANOVA).
According to Verhage (1964).
Measured with the Dutch Adult Reading Test (DART). DART-scores were missing for 1 healthy control.
Illness duration information was missing for 1 patient.
Some patients were using multiple antipsychotic medications.
Fig. 3Overview of task.
Fig. 4A. Association between clinical insight (SAI-E subscale relabeling of symptoms) and brain activation during suppression.
B. Association between cognitive insight (BCIS subscale self-reflectiveness) and brain activation during suppression.
Associations between insight and activation or connectivity during emotion regulation.
| Hemisphere | k voxels | MNI coordinates | Z | |||
|---|---|---|---|---|---|---|
| x | y | z | ||||
| Caudate, putamen, thalamus, insula | L | 211 | −26 | 0 | 10 | 4.61 |
| −24 | −6 | 16 | 4.14 | |||
| −16 | −8 | 22 | 4.04 | |||
| Insula, caudate | R | 251 | 22 | −16 | 20 | 4.59 |
| 36 | −24 | 24 | 3.91 | |||
| 32 | −32 | 20 | 3.87 | |||
| Precentral gyrus, postcentral gyrus | R | 162 | 28 | −32 | 68 | 4.12 |
| 34 | −20 | 62 | 4.02 | |||
| 20 | −24 | 64 | 3.63 | |||
| Superior occipital gyrus, cuneus | L | 228 | −14 | −82 | 42 | 4.11 |
| −22 | −82 | 30 | 4.09 | |||
| −28 | −72 | 18 | 3.67 | |||
| Middle occipital gyrus, superior occipital gyrus, cuneus | R | 209 | 28 | −76 | 30 | 3.83 |
| 14 | −78 | 28 | 3.74 | |||
| 20 | −84 | 26 | 3.52 | |||
| Precentral gyrus, postcentral gyrus | L | 113 | −34 | −18 | 44 | 4.85 |
| −46 | −12 | 38 | 3.49 | |||
| Middle cingulate gyrus | L | 121 | −12 | −6 | 40 | 4.38 |
| −10 | 2 | 34 | 3.73 | |||
| −6 | −14 | 40 | 3.68 | |||
| Precentral gyrus, postcentral gyrus | R | 224 | 46 | −16 | 36 | 4.32 |
| 36 | −18 | 40 | 4.09 | |||
| 48 | −4 | 32 | 4.05 | |||
| Middle occipital gyrus (lingual gyrus, fusiform gyrus) | R | 104 | 30 | −80 | 0 | 4.16 |
| 28 | −68 | 2 | 3.73 | |||
| 26 | −86 | −8 | 3.45 | |||
All results of regression analyses are shown with an initial threshold of p < 0.001 (uncorrected) and cluster-level FWE-corrected p < 0.05.
Abbreviations: L = left; R = right.
Fig. 5Association between clinical insight (SAI-E subtotal scores) and brain connectivity during suppression. Left: seed region in the midline medial frontal gyrus. Right: association between clinical insight (SAI-E subtotal scores) and connectivity with seed region during suppression.